This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Davide Corti
SVP, Antibody Research at Humabs BioMed SA, a subsidiary of Vir Bi

Profile

Dr. Davide Corti obtained his bachelor in Pharmaceutical Biotechnology at the University of Milan and his Ph.D. in Immunology at the University of Bern, followed by postdoctoral training in Antonio Lanzavecchia’s laboratory at the Institute for Research in Biomedicine where he further developed and optimized two methods for the isolation of human monoclonal antibodies out of memory B cells and plasma cells. In 2009 he was the Chief Scientific Officer at Humabs, where he leads a research group to isolate monoclonal antibodies against multiple infectious disease viral and bacterial agents. Starting from 2012 he collaborated with MedImmune on the isolation of human antibodies against multiple target pathogens like Rhinovirus, Influenza B, Klebsiella and Staphylococcus. His teams’ efforts to date have generated six clinical stage candidates, MEDI8852 and VIR-2482 targeting Influenza A, mAb114 targeting Ebola virus, anti-CMV antibodies, VIR-3434 taregting HBV and VIR-7831 targeting SARS-CoV-2. Dr. Corti has published more than 100 peer reviewed journal articles and helds more than 20 patents. Humabs was acquired by Vir Biotechnology in 2017 to become its subsidiary in Bellinzona, Switzerland. Dr. Davide Corti is now Senior Vice President, leading Antibody Research at Vir.

Agenda Sessions

  • COVID Antibody Treatment Successes, Failures and Models: What Have We Learned?

    11:45
  • Tackling COVID-19 with Human Neutralizing Antibodies

    On Demand

Speakers at this event